EFFICACY AND SAFETY OF VONOPRAZAN-BASED QUADRUPLE REGIMENS FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH PEPTIC ULCER: A POOLED ANALYSIS OF TWO PHASE III TRIALS

Xiaohua Hou  ¹     Jiangbin Wang  ²     Qin Du  ³     Fang Zhou  ⁴     Li Xie  ⁵     Liqun Gu  ⁶     Kentarou Kudou  ⁷     Shutian Zhang  ^8    
1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
² China-Japan Union Hospital of Jilin University, Changchun, China
³ The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
⁴ Takeda Pharmaceutical Company, Shanghai, China
⁵ Takeda Pharmaceutical Company, Beijing, China
⁶ Takeda Development Center Asia, Shanghai, China
⁷ Takeda Pharmaceutical Company, Osaka, Japan
⁸ Beijing Friendship Hospital, Capital Medical University, Beijing, China

Session
H. pylori (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)